Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b open-label single-arm study of BST-236 monotherapy in newly diagnosed AML patients unfit for standard induction
MOH_2018-07-03_002448Phase 2Active, not recruiting
- Sponsor
- BioSight
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aspacytarabine in acute myeloid leukemia (AML), sponsored by BioSight. Primary endpoint: Complete remission rate. Started Jun 2018; status: active, not recruiting.
02
Drugs
aspacytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2018-07-03_002448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-07-03_002448.